Kyowa Kirin has started selling KOMZIFTI (ziftomenib) in the United States, but the launch is not yet adding to its reported revenue. Under its strategic alliance with Kura Oncology, the two companies split US profit 50:50. Kyowa Kirin books its share as revenue when the net result is positive and as selling, general and administrative expense when it is negative. For the nine months to September 30, the net result was negative, so it went into expenses.
The US Food and Drug Administration approved KOMZIFTI in November 2025 for adults with relapsed or refractory acute myeloid leukaemia who carry a susceptible NPM1 mutation and have no satisfactory alternative treatment. Sales began in the US after that approval.
What the headline growth contains
Nine-month revenue was ¥384.9bn, up 10.2%. Core operating profit was ¥97.0bn, up 46.8%, and quarterly profit was ¥51.7bn, up 58.5%. These are cumulative figures, not a standalone third quarter.
Two items flatter the comparison. A weaker yen added ¥19.8bn to revenue and ¥8.5bn to core operating profit. Separately, Kyowa Kirin ended its collaboration with Amgen on KHK4083/AMG 451 and recognised the full remaining contract liability as revenue, which lifted technology revenue. The company gives no amount for that item in this document.
Research spending also fell, which helped core profit. Other expenses rose on contract-loss and impairment charges.
Kyowa Kirin left its full-year guidance unchanged: revenue of ¥520bn and core operating profit of ¥130bn.